

# **Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2018**

<https://marketpublishers.com/r/T2F9247AF62EN.html>

Date: October 2018

Pages: 107

Price: US\$ 3,500.00 (Single User License)

ID: T2F9247AF62EN

## **Abstracts**

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2018

### **SUMMARY**

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) pipeline Target constitutes close to 30 molecules. Out of which approximately 27 molecules are developed by companies and remaining by the universities/institutes. The latest report Telomerase Reverse Transcriptase - Pipeline Review, H2 2018, outlays comprehensive information on the Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and anti-apoptosis. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 2, 10 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and



1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Male Health, Respiratory, Hematological Disorders and Women's Health which include indications Prostate Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Alzheimer's Disease, Breast Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer, Solid Tumor, Gastric Cancer, Ovarian Cancer, Aplastic Anemia, Benign Prostatic Hyperplasia, Bile Duct Cancer (Cholangiocarcinoma), Blood Cancer, Chronic Lymphocytic Leukemia (CLL), Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hormone-Sensitive Prostate Cancer, Idiopathic Pulmonary Fibrosis, Lung Adenocarcinoma, Lymphoma, Male Infertility, Melanoma, Metastatic Biliary Tract Cancer, Metastatic Brain Tumor, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Pulmonary Fibrosis, Renal Cell Carcinoma, Sarcomas, Small-Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Women Infertility.

Furthermore, this report also reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)

The report reviews Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)



targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects

The report assesses Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49)



Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



## Contents

Introduction

Global Markets Direct Report Coverage

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or  
Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or  
Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development  
Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or  
Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment  
Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or  
Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in  
Therapeutics Development

Asterias Biotherapeutics Inc

e-Therapeutics Plc

F. Hoffmann-La Roche Ltd

GemVax & KAEL Co Ltd

Geron Corp

Inovio Pharmaceuticals Inc

Invectys SA

Komipharm International Co Ltd

Mediolanum farmaceutici SpA

Takis Srl

Telocyte LLC

TILT Biotherapeutics Ltd

Ultimovacs AS

Vaxon Biotech

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or  
Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles  
Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian  
Cancer - Drug Profile



Product Description

Mechanism Of Action

R&D Progress

ASTVAC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASTVAC-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETS-2300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate TERT for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imetelstat sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-1400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5401 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress



INVAC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KML-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ribovax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Telomerase for Men Infertility and Women Infertility - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Telomerase for Lung Cancer and Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TERT for Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Telomerase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEL-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

telin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tertomotide - Drug Profile

Product Description



Mechanism Of Action  
R&D Progress  
TILT-234 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
TK-005 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
UCPVax - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
UV-1 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Vbx-011 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Vbx-016 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Vbx-021 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Vbx-026 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Vx-001 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Vx-006 - Drug Profile



Product Description

Mechanism Of Action

R&D Progress

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or

Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Products

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or

Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products

Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or

Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Product Development

Milestones

Featured News & Press Releases

Sep 04, 2018: Asterias Biotherapeutics announces positive outcome from Second Safety Review Committee Meeting and open enrollment for VAC2 clinical trial in non-small cell lung cancer (NSCLC)

Aug 20, 2018: Inovio doses first patient in Phase I/IIa of INO-5401 and atezolizumab

Jul 11, 2018: Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)

Jun 28, 2018: Southampton vaccinate first patient to phase 1 study

Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron's PD-1 Inhibitor

Jun 18, 2018: Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress

Jun 12, 2018: Cancer Research Uk Tests First Of Its Kind Vaccine To Treat Lung Cancer

May 17, 2018: Geron Announces Oral Presentation at European Hematology Association Congress

May 16, 2018: Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress

Apr 25, 2018: Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2

Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia

Mar 24, 2018: New Preclinical Data for THIO in BRAF-Mutant Mouse Melanoma Models

Jan 30, 2018: CNIO researchers cure lung fibrosis in mice with a gene therapy that lengthens telomeres

Jan 04, 2018: Asterias Biotherapeutics Provides Update on ASTVAC-2

Dec 19, 2017: PharmaJet and Invectys Partner in Phase II Clinical Trial of DNA Cancer Vaccine



Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indications, H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.2), H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Products under Development by Companies, H2 2018 (Contd.2), H2 2018  
Products under Development by Companies, H2 2018 (Contd.3), H2 2018  
Number of Products under Investigation by Universities/Institutes, H2 2018  
Products under Investigation by Universities/Institutes, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by Asterias Biotherapeutics Inc, H2 2018  
Pipeline by e-Therapeutics Plc, H2 2018  
Pipeline by F. Hoffmann-La Roche Ltd, H2 2018  
Pipeline by GemVax & KAEL Co Ltd, H2 2018  
Pipeline by Geron Corp, H2 2018  
Pipeline by Inovio Pharmaceuticals Inc, H2 2018  
Pipeline by Invectys SA, H2 2018  
Pipeline by Komipharm International Co Ltd, H2 2018  
Pipeline by Mediolanum farmaceutici SpA, H2 2018  
Pipeline by Takis Srl, H2 2018  
Pipeline by Telocyte LLC, H2 2018  
Pipeline by TILT Biotherapeutics Ltd, H2 2018  
Pipeline by Ultimovacs AS, H2 2018  
Pipeline by Vaxon Biotech, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd.1), H2 2018  
Dormant Products, H2 2018 (Contd.2), H2 2018  
Dormant Products, H2 2018 (Contd.3), H2 2018  
Discontinued Products, H2 2018  
Discontinued Products, H2 2018 (Contd.1), H2 2018







## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Top 10 Indications, H2 2018  
Number of Products by Mechanism of Actions, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Routes of Administration, H2 2018  
Number of Products by Stage and Routes of Administration, H2 2018  
Number of Products by Molecule Types, H2 2018  
Number of Products by Stage and Molecule Types, H2 2018

### COMPANIES MENTIONED

Asterias Biotherapeutics Inc  
e-Therapeutics Plc  
F. Hoffmann-La Roche Ltd  
GemVax & KAEL Co Ltd  
Geron Corp  
Inovio Pharmaceuticals Inc  
Invectys SA  
Komipharm International Co Ltd  
Mediolanum farmaceutici SpA  
Takis Srl  
Telocyte LLC  
TILT Biotherapeutics Ltd  
Ultimovacs AS  
Vaxon Biotech



## I would like to order

Product name: Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/T2F9247AF62EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T2F9247AF62EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



